Add this topic to your myFT Digest for news straight to your inbox
CEO Kåre Schultz says cuts will be made carefully and ‘not in a harvest way’
Shares in health insurance group rise on takeover reports sending valuation to $60bn
Israeli pharma company to face price competition on blockbuster treatment
Chairman Sol Barer looks to Kåre Schultz to help revive flagging Israeli drugmaker
Teva appoints Kare Schultz having been previously linked with AstraZeneca’s chief
Kare Schultz’s appointment offers hope for the Israeli drugmaker’s shareholders
Teva hires Kare Schultz as new chief executive after other approaches fail
Intensified competition hurts copycat pharma groups while buyers drive harder bargain
Pharma business models have been disrupted in two short years
Israeli drugmaker’s shares plunge after writedown of US division and dividend cut
Brussels alleges Israeli group agreed not to market generic version of sleep aid
International Edition